This poster, presented at SSIEM 2026, outlines the design of the EPIPHENY Phase 3b study, which evaluates the effects of long-term sepiapterin on neurocognitive function in children with phenylketonuria (PKU)
The Society for the Study of Inborn Errors of Metabolism (SSIEM)
The Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium is a yearly conference bringing together clinicians and scientists to discuss the challenges and opportunities in the field of inborn errors of metabolism.
Please select the resource of interest below:
|
Congress
Topic
Type
Year
This poster, presented at SSIEM 2026, examines the long-term efficacy and safety of sepiapterin in people with phenylketonuria (PKU) and controlled blood phenylalanine (Phe) levels
This poster, presented at SSIEM 2026, examines the efficacy and safety of sepiapterin in individuals with phenylketonuria (PKU) and baseline phenylalanine (Phe) levels ≥900 µmol/L, including its impact on blood Phe levels and dietary protein tolerance
This poster, presented at SSIEM 2026, evaluates mixing and compatibility studies of sepiapterin to inform additional administration approaches for people with phenylketonuria (PKU)
This poster, presented at SSIEM 2026, discusses null PAH variants in individuals with phenylketonuria (PKU) and their association with disease severity and treatment response
This poster, presented at SSIEM 2026, highlights the efficacy and safety of sepiapterin in participants with phenylketonuria (PKU) who were already receiving sapropterin at study screening in the AMPLIPHY Phase 3 study
Always consult the prescribing information before prescribing any products
MED-US-CORP-2500008 | November 2025
MED-US-PKU-2600003 | February 2026